Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today that leadership will participate in four upcoming virtual investor conferences, as follows:

• SVB Leerink Partners 10^th Annual Global Healthcare Conference – Tuesday, February 23, 2021
• Cowen 40^th Annual Healthcare Conference – Wednesday, March 3, 2021
• Barclays Global Healthcare Conference – Tuesday, March 9, 2021
• Guggenheim Targeted Protein Degradation Day – Tuesday, March 16, 2021

About Monte Rosa

Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland. For more information, visit www.monterosatx.com.